Loading stock data…
$138.49-6.39 (-4.41%)
Protagonist Therapeutics, Inc.
Protagonist Therapeutics, Inc. in the Healthcare sector is trading at $138.49 with a market capitalization of $9.3B. Wall Street consensus targets $178.21 (14 analysts), implying a +28.7% move over the next 12 months. The stock is currently 14% below its 52-week high of $160.81, remaining 22.5% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $213.47M↑ | $56.37M↑ | $7.44M↑ | $4.71M↓ | $5.55M |
| Gross Profit | — | — | — | — | — |
| Operating Income | $158.77M↑ | -$3.65M↑ | -$50.35M↓ | -$46.42M↓ | -$42.04M |
| Net Income | $162.85M↑ | $3.78M↑ | -$44.38M↓ | -$39.34M↓ | -$34.77M |
Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States. It develops Icotyde, a first-in-class investigational targeted oral peptide for the treatment of adults and pediatric patients 12 years of age and ol...